Medicare AdvantagePrior AuthMedium impact
Sutent (sunitinib) (New)
Humana·Oncology, Urology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Sutent (sunitinib) effective January 1, 2026, covering seven cancer indications including renal cell carcinoma, GIST, and pancreatic neuroendocrine tumors. All requests require prior authorization with specific clinical criteria and documentation for Medicare Advantage plans.
Action Required
By January 1, 2026: Billing team must update prior authorization workflow to require PA for all Sutent (sunitinib) prescriptions for Medicare Advantage patients. Train providers on seven covered indications and specific clinical criteria including stage requirements, prior treatment failures, and exclusions. Update EMR templates to capture required documentation for renal cell carcinoma, GIST, pancreatic neuroendocrine tumors, thymomas, thyroid carcinoma, and angiosarcoma. Claims will be denied without proper prior authorization.